Disponible en / Available in:
Español
In this new informative capsule, our physiotherapist Mar Gallego explains the correct use of PARI eFlow Rapid nebulizer in Cystic Fibrosis.
Autogenic Drainage and nebulization
The Autogenous Drainage technique is the technique of choice in Cystic Fibrosis. This application includes the correct nebulization of medications. Professor Jean Chevaillier, creator of the Autogenous Drainage technique, actively collaborated in the design of PARI’s eFlow Rapid.
Correct use of the PARI eFlow Rapid nebulizer
PARI’s eFlow Rapid is one of the most used nebulizers, so our physiotherapist Marl Gallego teaches us how to use it correctly. During assembly, we must listen for the Chevaillier “click” to make sure it is properly assembled.
The importance of nebulizer position
The position of the nebulizer and the back of the person using it are basic for a productive nebulization session. If the nebulizer is not in a horizontal position, the residual volume of the product may not be correct, so you may be administering a different amount of medication than prescribed. You can watch our informative capsule on this topic here.
Easy Care for unclogging the mesh of PARI eFlow Rapid
It can happen that holes in the mesh remain clogged, so this capsule shows how to use PARI’s Easy Care to free those holes.
Cleaning and sterilization of PARI eFlow Rapid
We invite you to watch this vídeo of the Cystic Fibrosis Foundation which explains more specifically how to carry out these processes.
What is Cystic Fibrosis?
Cystic Fibrosis is a genetic, serious and degenerative disease that to date has no cure.
It mainly affects the respiratory, digestive, reproductive and sweat glands.
The treatment for Cystic Fibrosis includes antibiotherapy, a healthy and hypercaloric nutrition and respiratory physiotherapy combined with endurance exercises.
You can see the infographic published by the Cystic Fibrosis Spanish Federation in this link (Spanish version) or see how Dani tells us what this disease is for him in this vídeo (Spanish version).
Currently, more than 2000 mutations are known in the gene that is defective in people with Cystic Fibrosis, although only about 150 mutations are described as causing the disease.
Statistics show that 1 in 5,000 people in Spain has Cystic Fibrosis (1 in 6,400 in the Balearic Islands) and 1 in 35 people is a carrier of a gene that causes the disease (1 in 40 in the Balearic Islands).
In the Balearic Islands there are 76 known diagnosed cases, but statistics speak of between 85 and 90 possible cases.
The awareness project of the Respiralia Foundation aims to raise awareness of this disease in order to discover those cases of people who have Cystic Fibrosis but have not yet been diagnosed.
